AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer
Stockholm, Sweden, September 2, 2025 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Philipp Mathieu as Chief Financial Officer (CFO). Philipp is an experienced healthcare executive with two decades of leadership and investment experience across European and US markets. […]